Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121875 · ClinicalTrials.gov registry record
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 1
- Enrollment target
NCT00121875: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT00121875 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121875 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Growth hormone treatment improves body fat distribution but also causes insulin resistance. Scientists have recently linked insulin resistance with special stores of fat in the muscles, which can be measured by magnetic resonance imaging (MRI). The researchers hypothesize that growth hormone will paradoxically reverse the linkage between muscle fat stores and insulin resistance. To assess this association and to investigate the cause(s), the researchers will measure muscle fat stores during growth hormone treatment. Other parameters linked to insulin resistance (glucose tolerance, blood markers, and body composition) will also be assessed. This study may lead to improved strategies for monitoring growth hormone therapy.
Interventions
- DRUG somatropin (rDNA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121875
The ClinicalTrials.gov registry entry for NCT00121875 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which somatropin (rDNA) is the first listed.
NCT00121875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00121875 about?
NCT00121875 is a clinical study titled "Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature". Growth hormone treatment improves body fat distribution but also causes insulin resistance. Scientists have recently linked insulin resistance with special stores of fat in the muscles, which can be measured by magnetic resonance imaging (MRI). The researchers hypothesize that growth hormone will pa...
What is the current status of trial NCT00121875?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2005-06. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00121875?
The interventions under investigation include: somatropin (rDNA) (DRUG).
Who is sponsoring clinical trial NCT00121875?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.